Using a mouse model of human non-Hodgkin’s lymphoma, Stadel et al. demonstrated a significant reduction in tumor burden when selinexor was administered prior to, rather than concurrently with, CD19-directed CAR-T [21]. Here, CD19 is linked to neoplasm.